These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19896447)

  • 1. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.
    Whiteman MC; Li L; Wicker JA; Kinney RM; Huang C; Beasley DW; Chung KM; Diamond MS; Solomon T; Barrett AD
    Vaccine; 2010 Jan; 28(4):1075-83. PubMed ID: 19896447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness.
    Whiteman MC; Wicker JA; Kinney RM; Huang CY; Solomon T; Barrett AD
    Vaccine; 2011 Dec; 29(52):9702-10. PubMed ID: 21945257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain.
    Welte T; Xie G; Wicker JA; Whiteman MC; Li L; Rachamallu A; Barrett A; Wang T
    Vaccine; 2011 Jun; 29(29-30):4853-61. PubMed ID: 21549792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.
    Zlatkovic J; Stiasny K; Heinz FX
    J Virol; 2011 Mar; 85(5):1994-2003. PubMed ID: 21147919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
    Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
    J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain.
    Kumar M; O'Connell M; Namekar M; Nerurkar VR
    Viruses; 2014 Jun; 6(6):2328-39. PubMed ID: 24915459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.
    Li N; Zhang YN; Deng CL; Shi PY; Yuan ZM; Zhang B
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum.
    Whiteman MC; Popov V; Sherman MB; Wen J; Barrett AD
    J Virol; 2015 Jan; 89(2):1474-8. PubMed ID: 25392222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a human live attenuated West Nile infectious DNA vaccine: Suitability of attenuating mutations found in SA14-14-2 for WN vaccine design.
    Yamshchikov V; Manuvakhova M; Rodriguez E
    Virology; 2016 Jan; 487():198-206. PubMed ID: 26545140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NS1 and TLR3 in Pathogenesis and Immunity of WNV.
    Patel S; Sinigaglia A; Barzon L; Fassan M; Sparber F; LeibundGut-Landmann S; Ackermann M
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Molecular Determinant of West Nile Virus Secretion and Morphology as a Target for Viral Attenuation.
    Basset J; Burlaud-Gaillard J; Feher M; Roingeard P; Rey FA; Pardigon N
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.